Chronic lymphocytic leukemia/small lymphocytic lymphoma

This Phase 2 trial is testing a combination of three drugs—zanubrutinib, obinutuzumab, and venetoclax—in people with previously untreated chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL). The goal is to see if the combo can make …

This study tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 600 participants will receive either acalabrutinib plus venetoclax or venetoclax plus obinutuzumab. The goal is to see which com…

This early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …

This phase 2 trial is testing whether a sequence of four drugs—bendamustine, obinutuzumab, zanubrutinib, and venetoclax—can eliminate minimal residual disease in people with relapsed or refractory chronic lymphocytic leukemia (CLL). The study enrolls about 42 adults whose CLL has…

This early-phase trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for people with certain B-cell lymphomas or chronic lymphocytic leukemia that have come back or not responded to standard treatments. The therapy in…

This phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…

This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…

This study tests a treatment called JCAR017, a type of CAR T-cell therapy, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modi…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combinati…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This phase 2 trial tests whether combining lenalidomide (a drug that cuts off blood supply to cancer and boosts immunity) with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Th…

This study tests whether combining zanubrutinib (a BTK inhibitor) with rituximab (an antibody) can help control chronic lymphocytic leukemia or small lymphocytic lymphoma in people who have not had treatment before. About 60 participants will receive the combination, and research…

This phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…

This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look…

This early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…

This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…

This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…

This phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …

This study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …

This phase 2 trial tests a personalized approach for chronic lymphocytic leukemia (CLL). Patients first receive two oral drugs (zanubrutinib and venetoclax). Only those who still have detectable cancer cells after treatment get an additional infusion drug (obinutuzumab). The goal…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This study tests whether taking duvelisib on an irregular schedule can control chronic lymphocytic leukemia or small lymphocytic lymphoma as well as the standard daily dosing, but with fewer severe side effects. Fifteen adults with cancer that returned or didn't respond to prior …

This early-phase trial is testing a new drug called GNC-035, a tetra-specific antibody, in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and other blood cancers. The study aims to find a safe dose and check for side effects. Only 3 participants have been e…

This observational study tracks about 160 Chinese adults with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who take acalabrutinib as part of their normal care. Researchers will record how the drug is used, including doses and com…

This study follows 1,000 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in France to see how they are actually treated in everyday clinics, not just in controlled trials. Researchers will track which therapies patients receive, in what order, a…

This study looks at how the 'watch and wait' approach affects the quality of life of people with slow-growing lymphomas like CLL and follicular lymphoma. Researchers will ask 250 Korean patients to fill out questionnaires about their well-being and anxiety. The goal is to underst…